Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Biomarkers
  • Blood Glucose / drug effects
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Angiopathies / prevention & control*
  • Drug Administration Schedule
  • Glucagon-Like Peptide 1 / administration & dosage
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Liraglutide
  • Risk Factors

Substances

  • Biomarkers
  • Blood Glucose
  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1